Premium
P4‐454: A long‐term, open‐label extension study evaluating the safety of extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease
Author(s) -
Perhach James,
Graham Stephen
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.09.149
Subject(s) - memantine , tolerability , medicine , dosing , adverse effect , placebo , anesthesia , pharmacology , dementia , disease , alternative medicine , pathology
clusion of APOE e4 presence/absence as a covariate drastically reduces the strength of association for these SNPs indicating that these associations may be due to LDwith the APOE e4 allele. 36 SNPs showed a p-value lower than 10-5 when only 26 were expected by chance. Conclusions: These results provide further evidence that genetic variation in the APOE region is strongly associated with CSF Aß42 levels. More small p-values than would be expected by chance were detected. This could indicate that true positive results have not reached genome-wide significance levels due to lack of statistical power and that a larger sample is required. Finally, our findings will be strengthened by the analysis of imputed data from the 1,000 genomes project. These imputed genotypes will be available in March 2011 and will be analyzed before ICAD 2011 and included in our presentation.